SS
EWTX icon

Steve Schonfeld’s Edgewise Therapeutics EWTX Stock Holding History

Steve Schonfeld’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
255,202
+156,127
+158% +$5.38M 0.04% 407
2026
Q1 		$3.12M Buy
99,075
+39,749
+67% +$1.15M 0.02% 650
2025
Q4 		$1.47M Buy
59,326
+7,337
+14% +$147K 0.01% 974
2025
Q3 		$843K Sell
51,989
-115,351
-69% -$1.64M ﹤0.01% 1467
2025
Q2 		$2.19M Sell
167,340
-111,633
-40% -$1.61M 0.01% 927
2025
Q1 		$6.14M Buy
278,973
+10,464
+4% +$275K 0.04% 468
2024
Q4 		$7.17M Sell
268,509
-277,037
-51% -$8.82M 0.04% 397
2024
Q3 		$14.6M Buy
545,546
+467,412
+598% +$9.3M 0.1% 215
2024
Q2 		$1.41M Sell
78,134
-206,466
-73% -$3.6M 0.01% 1056
2024
Q1 		$5.19M Sell
284,600
-34,500
-11% -$548K 0.03% 630
2023
Q4 		$3.49M Buy
319,100
+202,200
+173% +$1.42M 0.02% 618
2023
Q3 		$670K Buy
116,900
+3,900
+3% +$26.5K 0.01% 1138
2023
Q2 		$876K Buy
113,000
+100,782
+825% +$850K 0.01% 1022
2023
Q1 		$81.5K Buy
+12,218
New +$113K ﹤0.01% 1725

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Steve Schonfeld's EWTX Position: Q2 2026 in Review

Steve Schonfeld increased its Edgewise Therapeutics (EWTX) stake by 158% in Q2 2026, buying an estimated $5.38M and bringing the position to 255,202 shares worth $10.4M. The position accounts for 0.04% of the portfolio, ranked #407.

Steve Schonfeld first reported a position in EWTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $14.6M in Q3 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Steve Schonfeld held 255,202 shares of Edgewise Therapeutics worth $10.4M as of Q2 2026.
  • Steve Schonfeld bought 156,127 Edgewise Therapeutics shares in Q2 2026, an estimated $5.38M.
  • Edgewise Therapeutics made up 0.04% of Steve Schonfeld's portfolio in Q2 2026, its #407 holding.
  • Steve Schonfeld first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Steve Schonfeld's Edgewise Therapeutics position peaked at $14.6M in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.